108050-54-0
Chemical Structure
Tilmicosin
Synonym(s): LY-177370; EL-870
- CAS No.: 108050-54-0
- Formula:C46H80N2O13
- Molecular Weight:869.13
IUPAC Name: (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-(((2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-7-(2-((3S,5R)-3,5-dimethylpiperidin-1-yl)ethyl)-16-ethyl-4-hydroxy-15-((((2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)-5,9,13-trimethyloxacyclohexadeca-11,13-diene-2,10-dione
InChIKey: JTSDBFGMPLKDCD-XVFHVFLVSA-N
SMILES: C[C@@H]([C@@H](CC1=O)O)[C@H]([C@H](C[C@H](C(/C=C/C(C)=C/[C@H](CO[C@H](O[C@H](C)[C@@H](O)[C@H]2OC)[C@@H]2OC)[C@@H](CC)O1)=O)C)CCN(C[C@H](C)C3)C[C@H]3C)O[C@@](O[C@H](C)[C@@H](O)[C@@H]4N(C)C)([H])[C@@H]4O
Biological Activity: Tilmicosin (LY-177370) is an orally active calcium channel antagonist and macrolide antibiotic with antimicrobial activity. Tilmicosin mainly acts on the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. Tilmicosin is effective in the treatment of respiratory diseases in livestock such as cattle, sheep and pigs. In addition, Tilmicosin has immunomodulatory and anti-inflammatory effects[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tilmicosin | 98.0% | Tilmicosin (LY-177370) is an orally active calcium channel antagonist and macrolide antibiotic with antimicrobial activity. Tilmicosin mainly acts on the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. Tilmicosin is effective in the treatment of respiratory diseases in livestock such as cattle, sheep and pigs. In addition, Tilmicosin has immunomodulatory and anti-inflammatory effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tilmicosin (Standard) | 99.52% | Tilmicosin (Standard) is the analytical standard of Tilmicosin. This product is intended for research and analytical applications. Tilmicosin (LY-177370) is an orally active calcium channel antagonist and macrolide antibiotic with antimicrobial activity. Tilmicosin mainly acts on the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. Tilmicosin is effective in the treatment of respiratory diseases in livestock such as cattle, sheep and pigs. In addition, Tilmicosin has immunomodulatory and anti-inflammatory effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tilmicosin-d3 | Tilmicosin-d3 is the deuterium labeled Tilmicosin. Tilmicosin (LY-177370) is an orally active calcium channel antagonist and macrolide antibiotic with antimicrobial activity. Tilmicosin mainly acts on the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. Tilmicosin is effective in the treatment of respiratory diseases in livestock such as cattle, sheep and pigs. In addition, Tilmicosin has immunomodulatory and anti-inflammatory effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ziv G, et al. Tilmicosin antibacterial activity and pharmacokinetics in cows. J Vet Pharmacol Ther. 1995 Oct;18(5):340-5. [Content Brief]
- [2]. Buret AG. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin. Can J Vet Res. 2010 Jan;74(1):1-10. [Content Brief]
- [3]. Cao XY, et al. Tilmicosin and tylosin have anti-inflammatory properties via modulation of COX-2 and iNOS gene expression and production of cytokines in LPS-induced macrophages and monocytes. Int J Antimicrob Agents. 2006 May;27(5):431-8. [Content Brief]
- [4]. Ibrahim AE, et al. Modulating Effects of Spirulina platensis against Tilmicosin-Induced Cardiotoxicity in Mice. Cell J. 2015 Spring;17(1):137-44. [Content Brief]
- [5]. Zhang N, et al. Pharmacokinetic and Pharmacodynamic integration of tilmicosin against Mycoplasma gallisepticum in the target infection site in chickens. Front Vet Sci. 2022 Sep 29;9:952599. [Content Brief]
- [6]. Veenhuizen MF, et al. Analysis of reports of human exposure to Micotil 300 (tilmicosin injection). J Am Vet Med Assoc. 2006 Dec 1;229(11):1737-42. [Content Brief]
